European Patent Office

T 0694/16 vom 15.05.2019

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2019:T069416.20190515
Datum der Entscheidung
15. Mai 2019
Aktenzeichen
T 0694/16
Antrag auf Überprüfung von
-
Anmeldenummer
08766831.5
Verfahrenssprache
Englisch
Verteilung
An die Kammervorsitzenden verteilt (C)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
FOOD COMPOSITION FOR PRODROMAL DEMENTIA PATIENTS
Name des Antragstellers
N.V. Nutricia
Name des Einsprechenden
Fresenius Kabi Deutschland GmbH
Nestec S.A.
Kammer
3.3.09
Leitsatz
-
Schlagwörter
Main request: sufficiency of disclosure (no)
Auxiliary request 4: added matter (no), sufficiency of disclosure (yes), novelty (yes), priority right (yes)
Orientierungssatz
If a claim is directed to a known compound or composition for use in a therapeutic method of treatment or prevention of a disease, and the claim specifies that the subject to be treated displays a clearly defined and detectable marker, which is not displayed by all subjects affected by or likely to develop that disease, then the purposive selection of the patients displaying the marker for the specified treatment is a functional feature characterising the claim. (Points 5.1-5.21 of the Reasons)

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division for further prosecution upon the basis of auxiliary request 4 filed under cover of a letter dated 6 June 2016.